Long-term mortality assessment of multidrug-resistant tuberculosis patients treated with delamanid
- PMID: 25700385
- PMCID: PMC4416109
- DOI: 10.1183/09031936.00176314
Long-term mortality assessment of multidrug-resistant tuberculosis patients treated with delamanid
Abstract
MDR-TB patients treated with 6 months or more of delamanid had significantly lower likelihood of mortality
Conflict of interest statement
Conflict of interest: Disclosures can be found alongside the online version of this article at
References
-
- Lienhardt C, Raviglione M, Spigelman M, et al. . New drugs for the treatment of tuberculosis: needs, challenges, promise, and prospects for the future. J Infect Dis 2012; 205: Suppl. 2, S241–S249. - PubMed
-
- Ryan NJ, Lo JH. Delamanid: first global approval. Drugs 2014; 74: 1041–1045. - PubMed
-
- Gler MT, Skripconoka V, Sanchez-Garavito E, et al. . Delamanid for multidrug-resistant pulmonary tuberculosis. N Engl J Med 2012; 366: 2151–2160. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials